Literature DB >> 24183524

Magnetic resonance imaging of pediatric pelvic masses.

Deepa R Pai1, Maria F Ladino-Torres.   

Abstract

Both benign and malignant pelvic masses are encountered in the pediatric population. Although ultrasonography remains the modality of choice for initial evaluation of a pediatric pelvic mass, in selected cases magnetic resonance (MR) imaging can add important diagnostic information. MR imaging has several advantages over ultrasonography and computed tomography, including superior contrast resolution and an ability to characterize abnormalities based on unique tissue characteristics. MR evaluation assists in lesion characterization, presurgical planning, and staging when a malignancy is suspected. MR imaging also offers a nonionizing imaging modality for long-term follow-up of patients undergoing therapy for malignant pelvic masses.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Pelvic masses; Rhabdomyosarcoma; Surgical planning

Mesh:

Year:  2013        PMID: 24183524     DOI: 10.1016/j.mric.2013.07.002

Source DB:  PubMed          Journal:  Magn Reson Imaging Clin N Am        ISSN: 1064-9689            Impact factor:   2.266


  3 in total

Review 1.  Ultrasonographic and multimodal imaging of pediatric genital female diseases.

Authors:  Maria Grazia Caprio; Marco Di Serafino; Alessia De Feo; Elvira Guerriero; Teresa Perillo; Luigi Barbuto; Norberto Vezzali; Eugenio Rossi; Federica Ferro; Gianfranco Vallone; Cinzia Orazi
Journal:  J Ultrasound       Date:  2019-02-19

Review 2.  What MRI can tell us about neurogenic tumors and rhabdomyosarcoma.

Authors:  M Beth McCarville
Journal:  Pediatr Radiol       Date:  2016-05-26

3.  MR imaging in discriminating between benign and malignant paediatric ovarian masses: a systematic review.

Authors:  Lotte W E van Nimwegen; Annelies M C Mavinkurve-Groothuis; Ronald R de Krijger; Caroline C C Hulsker; Angelique J Goverde; József Zsiros; Annemieke S Littooij
Journal:  Eur Radiol       Date:  2019-09-16       Impact factor: 5.315

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.